Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 17/20 | 0.48 |
| ▸ | CDK2 | P24941 | 10/20 | 0.48 |
| ▸ | JUN | P05412 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.40 |
| ▸ | INSR | P06213 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31500952 | 0.90 | CDK2 (0.53) | IGF1RCDK2JUNMAPK8MAPK9 | |
| SCHEMBL22252904 | 0.83 | MAPK9 (0.55) | IGF1RCDK2JUNMAPK8MAPK9 | |
| SCHEMBL22252966 | 0.81 | IRAK4 (0.48) | IGF1RCDK2JUNMAPK8MAPK9 | |
| SCHEMBL22228848 | 0.80 | CDK2 (0.53) | IGF1RCDK2JUNMAPK8MAPK9 | |
| SCHEMBL20460640 | 0.77 | MAPK10 (0.58) | IGF1RCDK2JUNMAPK8MAPK9 | |
| SCHEMBL22228925 | 0.74 | CDK2 (0.51) | IGF1RCDK2JUNMAPK8MAPK9 | |
| SCHEMBL22228927 | 0.74 | CDK2 (0.51) | IGF1RCDK2JUNMAPK8MAPK9 | |
| SCHEMBL22252783 | 0.74 | IGF1R (0.49) | IGF1RCDK2IRAK4KCNH2CDK9 | |
| SCHEMBL22252977 | 0.72 | FLT3 (0.55) | IGF1RCDK2JUNMAPK8MAPK9 | |
| SCHEMBL22228694 | 0.71 | CDK2 (0.62) | IGF1RCDK2JUNMAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111245-B2 | Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2021-09-07 | — | — | US | disclosed |
| US-20200231586-A1 | DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231586-A1 | DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS | CDK2, CDKL1, CDKL2 | IGF1R 1295/4885CDK2 1/4885JUN 607/4885 |
| US-11111245-B2 | Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents | CDK2, CDKL1, CDKL2 | IGF1R 1295/4885CDK2 1/4885JUN 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.